Hemorrhagic Fever With Renal Syndrome Clinical Trial
Official title:
Study on the Relationship Between Neutrophil-mediated Thrombocytopenia and the Condition and the Course of Disease in Patients With HFRS
Thrombocytopenia is an important pathological feature of HFRS(Hemorrhagic Fever With Renal Syndrome, HFRS). However, the cause of thrombocytopenia in HFRS is not yet fully understood. Neutrophils, as the largest number of white blood cells in the human body, can widely participate in the immune process of viral infections. Previous studies have found that the neutrophils of patients with acute myocardial infarction can interact with activated platelets and further mediate platelet phagocytosis.Therefore, this study aims to systematically elucidate the immunological process of neutrophil mediated thrombocytopenia in patients with HFRS by exploring the correlation between platelet activation, neutrophil activation and neutrophil proportion of adherent / phagocytic platelets peripheral blood of HFRS patients, and to analyze its relationship with the course of HFRS disease, which lays a theoretical foundation for further understanding the pathogenesis of HFRS and provides a basis for clinical use.
Status | Recruiting |
Enrollment | 28 |
Est. completion date | February 28, 2024 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age =18 years; - Clinical diagnosis meets the diagnostic criteria of the national HFRS prevention and treatment plan (Hantavirus-specific IgM antibody is positive). The classification and staging standards of HFRS patients are based on the "Expert Consensus of Shaanxi Province on Diagnosis and Treatment of Hemorrhagic Fever with Renal Syndrome". Exclusion Criteria: - Age <18 years; - Have a history of kidney disease; - Have a history of liver disease; - Have a history of malignant tumor; - Receive dialysis treatment before admission; - Combined with hypertension, coronary heart disease and diabetes history; - Combined with HIV infection and patients with autoimmune diseases and pregnancy. |
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital of Xian Jiaotong university | Xi'an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital Xi'an Jiaotong University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in the platelet activation ratio, % | flow cytometry | through study completion, an average of 2 year | |
Primary | Changes in neutrophils MPO content, MFI | enzyme-linked immunosorbent assay | through study completion, an average of 2 year | |
Primary | Changes in the neutrophils with adherent platelets, % | flow cytometry | through study completion, an average of 2 year | |
Primary | Changes in the neutrophils with internalized platelets, % | flow cytometry | through study completion, an average of 2 year | |
Secondary | Changes in Neutrophils Mac-1 expression, MFI | flow cytometry | through study completion, an average of 2 year | |
Secondary | Changes in the platelets with phosphatidylserine exposure,% | flow cytometry | through study completion, an average of 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00868946 -
Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
|
Phase 2 | |
Recruiting |
NCT04323904 -
Hantavirus Registry - HantaReg
|
||
Completed |
NCT02116205 -
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
|
Phase 2 | |
Completed |
NCT02455375 -
Diagnostic of Puumala Virus Infection in France
|
||
Completed |
NCT01502345 -
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
|
Phase 1 | |
Enrolling by invitation |
NCT00623168 -
Ribavirin for Hemorrhagic Fever With Renal Syndrome
|
Phase 2 |